RxDoctor Payments Data

Gayland Yee, MD

Adult Medicine · Kihei, HINPI 1083790653

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $728 of the $844 with a category attached, or 86.3%. 14 manufacturers reported payments, led by Pfizer at 24.2% of the total. Reporting peaked in 2019 at $428 and has fallen 72.9% since, to $116 in 2024.

$844in general payments, 2019–2025

Across 42 payments — averaging $20.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$204
  • AstraZeneca$142
  • Novo Nordisk$116
  • Nxstage Medical, Inc.$111
  • AbbVie$50
  • Merck$38
  • plus $183 from 8 others

What the payments were for

  • Food & beverage$72886%
  • Education$11614%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult medicine providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$120,325
Medicare patients
246
Services billed
1,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate14$118,085
OzempicSemaglutide82$100,118
EliquisApixaban56$55,794
JanuviaSitagliptin Phosphate36$49,486
XareltoRivaroxaban24$31,706
JanumetSitagliptin Phos/Metformin Hcl18$22,761
VascepaIcosapent Ethyl11$11,191
InvokanaCanagliflozin13$11,090
JardianceEmpagliflozin11$10,736
Cephalexin40$10,418
FarxigaDapagliflozin Propanediol12$9,927
SymbicortBudesonide/Formoterol Fumarate38$9,499
Atorvastatin Calcium386$8,678
Rosuvastatin Calcium210$7,048
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$6,456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$116$100,11882 claims
MerckJanuvia, Janumet$38$72,24854 claims
PfizerEliquis$204$55,79456 claims
AstraZenecaFarxiga, Symbicort$142$19,42750 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Hawaiion file to place this against a meaningful peer group, so we don't.

Other adult medicine in Kihei

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →